Patents Assigned to GlaxoSmithKline
-
Patent number: 12128096Abstract: The disclosure provides synthetic (e.g. recombinant) pneumococcal saccharides comprising one or more repeat unit(s) ?4)-?-D-Glcp-(1?4)-[Gro-(2?P?3)]-?-D-Galp-(1?4)-?-L-Rhap-(1?. Also provided are conjugates comprising a ?4)-?-D-Glcp-(1?4)-[Gro-(2?P?3)]-?-D-Galp-(1?4)-?-L-Rhap-(1?, immunogenic compositions, vaccines and their use in preventing or treating infection by Streptococcus pneumoniae.Type: GrantFiled: May 31, 2022Date of Patent: October 29, 2024Assignee: GlaxoSmithKline Biologicals SAInventors: Amirreza Faridmoayer, Rainer Follador, Stefan Jochen Kemmler, Michael Thomas Kowarik, Gerald Johann Posch, Fabio Serventi
-
Patent number: 12122828Abstract: Provided herein are interleukin 7 (IL-7) binding proteins, pharmaceutical compositions and their use in the treatment or prevention of a disease or condition.Type: GrantFiled: September 5, 2023Date of Patent: October 22, 2024Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Gerben Bouma, Edward Thomas Coulstock, David Dixon, Stephanie Hopley, Alan Peter Lewis, Jessica Lynn Neisen
-
Publication number: 20240299404Abstract: Methods of treating pruritus in a mammal with a P2X3 antagonist are disclosed. Said P2X3 antagonist is preferably a compound of Formula (I). Said pruritus may be associated with an inflammatory skin disorder, an infectious skin disease, an autoimmune skin disease or a pregnancy-related skin disease. The P2X3 antagonist may be administered by intravenous administration, subcutaneous administration, oral administration, inhalation, nasal administration, topical administration or ophthalmic administration and may be used in conjunction with a NK-1 antagonist. The P2X3 antagonist acts by inhibiting pathological ATP release associated with hyperexcitability of afferent pruriceptive neurons, thus dampening peripheral hypersensitivity to itch via a broad mechanism independent on the pathological stimuli acting at itch receptors.Type: ApplicationFiled: May 16, 2024Publication date: September 12, 2024Applicant: GlaxoSmithKline Intellectual Property (No.3) LimitedInventors: Antonios MATZOURANIS, Nathalie CHAURET, Denis GARCEAU
-
Publication number: 20240293535Abstract: The present invention relates to a HSV2 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV1 in a subject. Also provided is a HSV1 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV2 when administered to a subject.Type: ApplicationFiled: January 18, 2022Publication date: September 5, 2024Applicant: GlaxoSmithKline Biologicals SAInventors: Johann MOLS, Marie TOUSSAINT
-
Publication number: 20240285755Abstract: The present invention relates to immunisation using carrier-formulated mRNA in conjunction with an adjuvant comprising a STING agonist, and to related aspects.Type: ApplicationFiled: May 20, 2022Publication date: August 29, 2024Applicant: GlaxoSmithKline Biologicals SAInventor: Emmanuel Jules HANON
-
Patent number: 12060431Abstract: The present invention relates to a CD20 binding antibody which is capable of depleting B cells, and a BLyS binding antibody which is capable of antagonizing BLyS, as a combination for use in the treatment of an autoimmune disorder. The invention also relates to dosages, duration of treatment and time lapses between administration of the CD20 binding antibody which is capable of depleting B cells, and the BLyS binding antibody which is capable of antagonizing BLyS.Type: GrantFiled: November 4, 2021Date of Patent: August 13, 2024Assignees: GlaxoSmithKline Intellectual Property Management Limited, GlaxoSmithKline Intellectual Property LimitedInventor: Robert B. Henderson
-
Publication number: 20240254247Abstract: The present disclosure relates to a B lymphocyte Stimulator (BlyS; B-cell activating factor; BAFF) antagonist for use in the treatment of Long Covid and/or post-acute sequelae SARS-COV-2 infection (PASC). Also disclosed is a BlyS antagonist for use in the treatment of an autoimmune condition induced following a viral infection. Such autoimmune conditions may be chronic, such as Long Covid. Also provided is a method for the treatment of an autoimmune condition induced following a viral infection comprising administering to a subject in need thereof a therapeutically effective amount of a BlyS antagonist.Type: ApplicationFiled: June 15, 2022Publication date: August 1, 2024Applicants: GlaxoSmithKline Intellectual Property Limited, GlaxoSmithKline Intellectual Property Management LimitedInventors: Robert Brian HENDERSON, Jeremy SOKOLOVE, André VAN MAURIK
-
Patent number: 12036285Abstract: The provided technology is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to antigens to form nOMV-antigen conjugates, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates is also provided.Type: GrantFiled: November 23, 2017Date of Patent: July 16, 2024Assignee: GlaxoSmithKline Biologicals SAInventors: Renzo Alfini, Francesca Micoli, Allan James Saul
-
Publication number: 20240189417Abstract: Provided herein are RNA that: are collectively self-amplifying in an intracellular environment, comprise N1-methyl-pseudouridines and uridines, and have a mole percentage or mole proportion of the N1-methylpseudouridines to the total of the uridines and the Ni-methylpseudouridines or a mole ration of the N1-methylpseudouridines to the uridines.Type: ApplicationFiled: January 29, 2024Publication date: June 13, 2024Applicant: GlaxoSmithKline Biologicals SAInventors: Giulietta MARUGGI, Qiongman KONG, Varnika ROY, Dong YU, Meng ZHANG
-
Patent number: 12005109Abstract: The present invention is in the field of conjugating native, non-detergent extracted, outer membrane vesicles (nOMV) to multiple antigens to form multi functionalized nOMV-antigen conjugated derivatives, which are particularly useful for immunogenic compositions and immunisation; processes for the preparation and use of such conjugates are also provided.Type: GrantFiled: August 8, 2018Date of Patent: June 11, 2024Assignee: GlaxoSmithKline Biologicals SAInventors: Renzo Alfini, Roberta Di Benedetto, Francesca Micoli, Allan James Saul
-
Patent number: 11999746Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.Type: GrantFiled: July 29, 2019Date of Patent: June 4, 2024Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Zehong Wan, Xiaomin Zhang, Jian Wang, Matthew Robert Sender, Eric Steven Manas, Raphael Anthony Rivero, Joseph E Pero, Christopher Ernst Neipp, Vipulkumar Kantibhai Patel
-
Publication number: 20240173290Abstract: The present disclosure relates to an inhibitor of human TRPM3 for use in the treatment or prevention of migraine. Combination therapies are also described. In other aspects, the present disclosure provides methods for identifying suitable patients, methods for identifying inhibitors of human TRPM3 and cell lines for use in such methods.Type: ApplicationFiled: January 12, 2022Publication date: May 30, 2024Applicants: GlaxoSmithKline Intellectual Property (No.3) Limited, 23andMe, Inc.Inventors: Janet Mary KUMAR, Colin Houston McPHEE, Adam Mohamed NAGUIB, Lea SAROV-BLAT, Claire Yvonne Marie TOWNSEND, Paul Bryan WREN, Clint Emest YOUNG
-
Publication number: 20240156949Abstract: The present invention is directed to nucleic acids suitable for use in treatment or prophylaxis of an infection with a coronavirus, such as a Coronavirus SARS-CoV-2 variant, or a disorder related to such an infection, such as COVID-19. The present invention is also directed to compositions, and vaccines. The compositions and vaccines comprise at least one of said nucleic acid sequences, and nucleic acid sequences in association with a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acids, the composition, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, such as a Coronavirus infection from a SARS-CoV-2 variant.Type: ApplicationFiled: October 26, 2023Publication date: May 16, 2024Applicants: GlaxoSmithKline Biologicals SA, CureVac SEInventors: Benjamin PETSCH, Dominik VAHRENHORST, Diego CHAVES MORENO, Janina GERGEN, Jessica Michelle DEVANT, Kristina KOVACIKOVA, Hans Wolfgang GROßE
-
Patent number: 11976057Abstract: This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.Type: GrantFiled: October 4, 2021Date of Patent: May 7, 2024Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Edward Brnardic, Michael Bury, Rodolfo Cadilla, Jon Collins, Yu Guo, Anthony Handlon, Huijie Li, Yue Li, Daniel Paone, Christie Schulte, Barry Shearer, Maben Ying, Guosen Ye, Huichang Zhang, Millard Hurst Lambert, III
-
Patent number: 11970480Abstract: Disclosed are compounds having the formula: wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.Type: GrantFiled: May 17, 2022Date of Patent: April 30, 2024Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Adam Kenneth Charnley, Michael G. Darcy, Jason W. Dodson, Xiaoyang Dong, Terry V. Hughes, Jianxing Kang, Lara Kathryn Leister, Yiqian Lian, Yue Li, John F. Mehlmann, Neysa Nevins, Joshi M. Ramanjulu, Joseph J. Romano, Gren Z. Wang, Guosen Ye, Daohua Zhang
-
Patent number: 11957749Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.Type: GrantFiled: December 14, 2018Date of Patent: April 16, 2024Assignee: GlaxoSmithKline Biologicals SAInventors: Virginia Ammendola, Babak Bayat, Clarisse Lorin, Ventzislav Bojidarov Vassilev, Alessandra Vitelli
-
Patent number: 11951161Abstract: Methods of inducing an immune response comprising at least two administrations of an adjuvanted immunogenic composition, wherein the second administration contains reduced amounts of antigen and adjuvant.Type: GrantFiled: March 11, 2020Date of Patent: April 9, 2024Assignee: GlaxoSmithKline Biologicals SAInventors: William Ripley Ballou, Jr., Arnaud Michel Didierlaurent, Robbert Gerrit Van Der Most
-
Patent number: 11945826Abstract: The present invention relates hydroxypyridoxazepine compounds, methods of making them, pharmaceutical compositions containing them and their use as Nrf2 activators. In particular, the invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, or a tautomer thereof, or a hydrate thereof.Type: GrantFiled: February 11, 2020Date of Patent: April 2, 2024Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Mark Elban, Michal Pawel Glogowski, Michael Clinton Koetting, Brian Griffin Lawhorn, Jay M. Matthews, Jaclyn Renee Patterson
-
Publication number: 20240091345Abstract: The present invention relates to a nucleic acid encoding a HSV2 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV1 in a subject. Also provided is a nucleic acid encoding a HSV1 Fc receptor or immunogenic fragment or variant thereof for use in generating a cross reactive immune response against HSV2 when administered to a subject.Type: ApplicationFiled: January 18, 2022Publication date: March 21, 2024Applicant: GlaxoSmithKline Biologicals SAInventors: Johann MOLS, Marie TOUSSAINT
-
Patent number: 11931405Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).Type: GrantFiled: July 28, 2022Date of Patent: March 19, 2024Assignees: GlaxoSmithKline Biologicals S.A.Inventors: Jeroen Geurtsen, Jan Theunis Poolman, Kellen Cristhina Fae, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier